OKG-0301

Phase 2Small molecule

OOkogen

OKG-0301 is one of 10 small molecule programs targeting Viral Conjunctivitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Viral ConjunctivitisActive, not recruiting

Viral ConjunctivitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

11 competitors in Viral Conjunctivitis

#DrugCompanyPhaseTrials

Decadron

AAspen Global Incorporated

Approved

—2

Betadine

BBecton, Dickinson and Company

Approved

—3

Artificial Tears

UUniversity Hospital of Patras

Phase 3

1 4

Toradol

JJavelin Pharmaceuticals

SHP640

2 6

Preservative Free Artificial Tear

UUniversity Hospital Sestre Milosrdnice

Phase 3

1 7

IVIEW-1201

IIVIEW Therapeutics Inc.

Phase 2

1 8

FST-100

Takeda

Phase 2

3 9

NVC-422

NNovaBay Pharmaceuticals, Inc.

Phase 2

1 10

OKG-0301

OOkogen

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Viral Conjunctivitis1 trial

OKG-0301 for the Treatment of Acute Adenoviral Conjunctivitis

Unknown status·OOkogen·Phase 2·NCT03856645·219 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for OKG-0301. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — OKG-0301 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for OKG-0301. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Okogen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: OOkogen

OKG-0301

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Viral Conjunctivitis1 trial

References

Drug Info

Quick Facts

Related News